

Carlos Silva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3137399/publications.pdf>

Version: 2024-02-01

32
papers

1,256
citations

394421

19
h-index

477307

29
g-index

33
all docs

33
docs citations

33
times ranked

986
citing authors

#	ARTICLE	IF	CITATIONS
1	Can we rely on total testosterone measurement to exclude hypogonadism in erectile dysfunction?. International Journal of Impotence Research, 2022, , .	1.8	1
2	The Role of Urinary Microbiota in Lower Urinary Tract Dysfunction: A Systematic Review. European Urology Focus, 2020, 6, 361-369.	3.1	30
3	Current stepwise recommendations for hypogonadism screening in erectile dysfunction are not cost-effective. International Journal of Impotence Research, 2020, 32, 297-301.	1.8	1
4	Misdiagnosis And Undertreatment Of Erectile Dysfunction In The Portuguese Primary Health Care. Sexual Medicine, 2019, 7, 177-183.	1.6	10
5	The Impact of Chronic Pelvic Ischemia on LUTS and Urinary Levels of Neuroinflammatory, Inflammatory, and Oxidative Stress Markers in Elderly Men: A Case-control Study. Urology, 2019, 123, 230-234.	1.0	15
6	Renal Cell Carcinoma with Venous Thrombus: Should Surgery Be Offered When Metastasis Is Present at Diagnosis?. Urologia Internationalis, 2018, 101, 387-390.	1.3	10
7	Use of botulinum toxin for genitourinary conditions: What is the evidence?. Toxicon, 2015, 107, 141-147.	1.6	10
8	Intrarenal artery pseudoaneurysm after blunt abdominal trauma: a case report of successful superselective angioembolization. Research and Reports in Urology, 2014, 6, 17.	1.0	5
9	Current medical treatment of lower urinary tract symptoms/BPH. Current Opinion in Urology, 2014, 24, 21-28.	1.8	56
10	Ulcerative and Nonulcerative Forms of Bladder Pain Syndrome/Interstitial Cystitis Do Not Differ in Symptom Intensity or Response to Onabotulinum Toxin A. Urology, 2014, 83, 1030-1034.	1.0	50
11	Single Incision Slings: Is There a Role?. Current Bladder Dysfunction Reports, 2013, 8, 19-24.	0.5	0
12	Botulinum toxin treatment for bladder dysfunction. International Journal of Urology, 2013, 20, 956-962.	1.0	20
13	Persistent Therapeutic Effect of Repeated Injections of Onabotulinum Toxin A in Refractory Bladder Pain Syndrome/Interstitial Cystitis. Journal of Urology, 2013, 189, 548-553.	0.4	72
14	Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU International, 2012, 110, 1721-1728.	2.5	81
15	Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU International, 2011, 107, 1950-1954.	2.5	19
16	Single-incision sling system as primary treatment of female stress urinary incontinence: prospective 12 months data from a single institution. BJU International, 2011, 108, 1616-1621.	2.5	24
17	Exploratory Study Assessing Efficacy and Complications of TVT-O, TVT-Secur, and Mini-Arc: Results at 12-Month Follow-Up. European Urology, 2011, 59, 940-944.	1.9	69
18	Distribution of the High-Affinity Binding Site and Intracellular Target of Botulinum Toxin Type A in the Human Bladder. European Urology, 2010, 57, 884-890.	1.9	89

#	ARTICLE	IF	CITATIONS
19	Trigonal Injection of Botulinum Toxin A in Patients with Refractory Bladder Pain Syndrome/Interstitial Cystitis. <i>European Urology</i> , 2010, 58, 360-365.	1.9	169
20	Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. <i>BMC Urology</i> , 2009, 9, 9.	1.4	34
21	Short-term assessment of a tension-free vaginal tape for treating female stress urinary incontinence. <i>BJU International</i> , 2009, 104, 225-228.	2.5	35
22	Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?. <i>Current Opinion in Urology</i> , 2009, 19, 347-352.	1.8	17
23	Kidney Hemorrhage After Renal Biopsy Treated by Percutaneous Superselective Segmental Renal Artery Embolization. <i>UroToday International Journal</i> , 2009, 02, .	0.1	1
24	Intraprostatic Botulinum Toxin Type A Injection in Patients Unfit for Surgery Presenting with Refractory Urinary Retention and Benign Prostatic Enlargement. Effect on Prostate Volume and Micturition Resumption. <i>European Urology</i> , 2008, 53, 153-159.	1.9	70
25	Bladder sensory desensitization decreases urinary urgency. <i>BMC Urology</i> , 2007, 7, 9.	1.4	32
26	Urodynamic Effect of Intravesical Resiniferatoxin in Patients with Neurogenic Detrusor Overactivity of Spinal Origin: Results of a Double-Blind Randomized Placebo-Controlled Trial. <i>European Urology</i> , 2005, 48, 650-655.	1.9	62
27	TRPV1 agonist therapies in bladder diseases. , 2005, , 211-225.		1
28	Botulinum toxin in the management of lower urinary tract dysfunction: contemporary update. <i>Current Opinion in Urology</i> , 2004, 14, 329-334.	1.8	25
29	The Effect Of Intravesical Resiniferatoxin In Patients With Idiopathic Detrusor Instability Suggests That Involuntary Detrusor Contractions Are Triggered By C-Fiber Input. <i>Journal of Urology</i> , 2002, , 575-579.	0.4	8
30	Desensitization of Bladder Sensory Fibers by Intravesical Resiniferatoxin, a Capsaicin Analog: Long-Term Results for the Treatment of Detrusor Hyperreflexia. <i>European Urology</i> , 2000, 38, 444-452.	1.9	115
31	Desensitization of Bladder Sensory Fibers by Intravesical Capsaicin has Long Lasting Clinical and Urodynamic Effects in Patients With Hyperactive or Hypersensitive Bladder Dysfunction. <i>Journal of Urology</i> , 1997, 157, 585-589.	0.4	125
32	Biomarkers in the Overactive Bladder Syndrome. , 0, , .		0